<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05116943</url>
  </required_header>
  <id_info>
    <org_study_id>13-004314</org_study_id>
    <secondary_id>5P01NS084974-07</secondary_id>
    <nct_id>NCT05116943</nct_id>
  </id_info>
  <brief_title>Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders</brief_title>
  <official_title>Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect CSF and blood samples that can be used in future&#xD;
      research studies to identify potential biomarkers in blood and cerebrospinal fluid (CSF)&#xD;
      collected in Amyotrophic Lateral Sclerosis (ALS) patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biomarkers are non-genetic elements in your blood and CSF that may help diagnose and monitor&#xD;
      ALS more easily. There are no readily available sources of longitudinal CSF, plasma or serum&#xD;
      samples from people with ALS, ALS-FTD or similar neurodegenerative disorders or their family&#xD;
      members for use in the identification of potential ALS biomarkers. Future research will&#xD;
      examine potential biomarkers in blood and CSF collected over time to see if they change over&#xD;
      time and can be used to diagnose and monitor people with ALS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2013</start_date>
  <completion_date type="Anticipated">January 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Blood serum collection</measure>
    <time_frame>10 years</time_frame>
    <description>Total number of blood serum samples collected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood plasma collection</measure>
    <time_frame>10 years</time_frame>
    <description>Total number of blood plasma samples collected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebrospinal fluid collection</measure>
    <time_frame>10 years</time_frame>
    <description>Total number of cerebrospinal fluid samples collected</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with ALS and similar neurodegenerative disorders and their family members will be&#xD;
        identified from patients seen in the Department of Neurology at Mayo Clinic Florida on the&#xD;
        basis of a diagnosis of ALS or a similar neurodegenerative disorder.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria - Patient with ALS, ALS-FTD or Similar Neurodegenerative Disease:&#xD;
&#xD;
          -  Clinical diagnosis of possible, laboratory-supported probable, probable or definite&#xD;
             ALS according to modified eL Escorial criteria, suspected ALS according to original el&#xD;
             Escorial criteria, or diagnosis of a similar neurodegenerative disorder.&#xD;
&#xD;
          -  Willing to provide consent, or assent, if physically unable to consent owing to&#xD;
             disease-related muscle weakness.&#xD;
&#xD;
        Inclusion Criteria - Spouse/Domestic Partner of Patients with ALS/ALS-FTD and Similar&#xD;
        Neurodegenerative Disorder or Subject with Family History of ALS, ALS-FTD or Similar&#xD;
        Neurodegenerative Disease:&#xD;
&#xD;
          -  No personal history of ALS, ALS-FTD or other motor neuron disease.&#xD;
&#xD;
          -  Subjects with family history of ALS, ALS-FTD the affected family member needs to be a&#xD;
             first, second, or third degree blood relative.&#xD;
&#xD;
          -  Willing to provide consent.&#xD;
&#xD;
        Exclusion Criteria - Subject with ALS/ALS-FTD or Similar Neurodegenerative Disease:&#xD;
&#xD;
          -  History of medical disorder that leaves in question whether neurological signs and&#xD;
             symptoms potentially related to a neurodegenerative disease may be caused by another&#xD;
             unrelated disorder.&#xD;
&#xD;
          -  Limited mental capacity rendering the subject unable to comply with lumbar puncture or&#xD;
             standard phlebotomy procedures.&#xD;
&#xD;
          -  For lumbar puncture, an increased risk of bleeding complications or allergy to local&#xD;
             anesthetic administered or skin antiseptic used for lumbar puncture.&#xD;
&#xD;
        Exclusion Criteria - Spouse/Domestic Partner of Patients with ALS/ALS-FTD and Similar&#xD;
        Neurodegenerative Disorder or Subject with Family History of ALS, ALS-FTD or Similar&#xD;
        Neurodegenerative Disease:&#xD;
&#xD;
          -  Limited mental capacity rendering the subject unable to comply with lumbar puncture or&#xD;
             standard phlebotomy procedures.&#xD;
&#xD;
          -  For lumbar puncture, an increased risk of bleeding complications or allergy to local&#xD;
             anesthetic administered or skin antiseptic used for lumbar puncture.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bjorn Oskarsson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Burch, BA</last_name>
      <phone>904-953-2000</phone>
      <email>burch.alex@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 2, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Bjorn E. Oskarsson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

